BioSpace News Archive

Zynerba Pharmaceuticals, Inc. today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, will present at the Ladenburg Thalmann 2022 Healthcare Conference on Thursday, September 29, 2022, at 3:00 p.m. ET, and host investor meetings.

Amydis Inc. today announced dosing of the first patients in the company’s Phase 1/2a trial evaluating AMDXP-2011P, a proprietary small molecule retinal imaging agent “retinal tracer” targeting deposits of alpha synuclein (ASYN) and the TAR DNA-binding protein 43 (TDP-43) in patients with Parkinson’s disease.

TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that management will participate in the following upcoming investor conferences.

Axogen, Inc. announced that it will participate in the 77th Annual Meeting of the American Society for Surgery of the Hand (ASSH) being held in Boston from September 29-October 1, 2022.

Plus Therapeutics, Inc. today announced that it has finalized and signed a grant contract with the Cancer Prevention & Research Institute of Texas (CPRIT) for its previously announced $17.6 million Product Development Research funding award.

Tonix Pharmaceuticals Holding Corp. today announced data from a retrospective observational database study in patients diagnosed with Long COVID at the International Association for the Study of Pain (IASP) 2022 World Congress on Pain, being held September 20-23, 2022, in Toronto, Canada.

Revolution Medicines, Inc. today announced the first patient was dosed in its Phase 1/1b monotherapy clinical trial of RMC-6291, an oral, selective, covalent KRASG12C(ON) Inhibitor designed to treat patients with cancers driven by the KRASG12C mutation.

Calyxt, Inc. (NASDAQ: CLXT) (“Calyxt”), a plant-based synthetic biology company, today announced that its Board of Directors is evaluating potential strategic alternatives to maximize shareholder value.

Compugen Ltd. is pleased to issue the following letter to shareholders.

UCB announced today it is presenting results from across its portfolio in generalized myasthenia gravis (gMG) at the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) annual meeting featuring the Myasthenia Gravis Foundation of America (MGFA) Scientific Session, September 21 – 24.